Company: TVRD
Filing Date: 2025-01-24
Form Type: CORRESP
Source: 0001104659-25-006051
Chunk: 1

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-24
Form: CORRESP
Chunk 1
---
us as        
 appropriate. Alternatively, tell us why you do not believe these revisions are appropriate.                                             |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the description of Proposal 1 on the Cover Page and
throughout the Amended Registration Statement.

| 2. | You state that, at the Effective Time, your outstanding options will be accelerated and that the number                                    
 of shares underlying such options will be adjusted based on the Reverse Stock Split. Please disclose whether the exercise price associated 
 with such options also will be adjusted based on the Reverse Stock Split.                                                                  |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on the Cover Page and pages 2,
4, 20 and 185 of the Amended Registration Statement to state that the exercise price of the options also will be adjusted based on
the Reverse Stock Split.

| 3. | Please disclose here the votes needed to approve the Reverse Stock Split Proposal. |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 5 of the Amended Registration
Statement to state the vote needed to approve the Reverse Stock Split Proposal.

MINTZ

| 4. | You state that there will be no material U.S. federal income tax consequences to your stockholders                                                
 as a result of the Merger. Please tell us what consideration you gave to disclosing any U.S. federal income tax consequences to your stockholders 
 resulting from the accelerated vesting of your outstanding restricted stock units at the Effective Time.                                          |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 5 of the Amended Registration
Statement to clarify that the U.S. federal income tax consequences to certain of the Company’s stockholders resulting from accelerated
vesting of RSUs at the Effective Time are not discussed in the Amended Registration Statement and encourages holders or beneficial owners
to consult their own tax advisors regarding any such consequences.

| 5. | Please revise your disclosure to clarify whether Cara Therapeutics, Inc. intends to complete the 
 Asset Disposition if the Merger is not consummated.                                              |

Response:
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 10 of the Amended Registration
Statement to clarify that the Company intends to complete the Asset Disposition if the Merger is not consummated subject to the receipt
of the requisite stockholder approval needed to approve the Asset Disposition in the event that the Merger is terminated.

|